immunopathogenesi
leukopenia
thrombocytopenia
patient
sever
acut
respiratori
syndrom
sar
unclear
order
explor
leukopenia
mechan
studi
sar
patient
previous
healthi
agematch
normal
control
pair
design
solubl
vascular
cell
adhes
solubl
fa
ligand
sfasl
plasma
measur
elisa
intracellular
activ
fragment
differ
leukocyt
determin
flow
cytometri
patient
sar
significantli
lower
lymphocyt
platelet
count
significantli
higher
sfasl
level
compar
healthi
control
level
correl
neg
total
leukocyt
platelet
count
posit
plasma
sfasl
level
intracellular
cleav
express
also
significantli
higher
lymphocyt
sar
patient
acut
phase
convalesc
stage
lymphopenia
thrombocytopenia
sar
patient
may
caus
part
enhanc
vascular
sequestr
associ
increas
level
howev
lymphopenia
may
due
enhanc
cell
death
inhibit
cell
adhes
activ
could
therefor
prevent
sar
patient
develop
thrombocytopenia
lymphopenia
sever
acut
respiratori
syndrom
sar
caus
human
coronaviru
origin
guangdong
provinc
china
spread
countri
immunopathogenesi
sar
clear
transmiss
rout
sar
clarifi
treatment
sar
patient
antiviru
therapi
antiinflammatori
corticosteroid
remain
highli
controversi
whether
direct
viral
pneumon
viru
cytotrop
tissu
damag
indirect
immunemedi
tissu
damag
sar
infect
remain
obscur
patient
sar
tend
prolong
fever
rapid
cours
pulmonari
infiltr
leukopenia
thrombocytopenia
lymphopenia
frequent
complic
coinfect
histolog
lung
necropsi
show
abund
foami
macrophag
multinucl
syncyti
cell
suggest
leukocyt
sequestr
interstiti
tissu
apoptosi
circulatori
leukocyt
implic
pathogenesi
earlier
studi
shown
sar
patient
elev
polymorphonuclear
leukocyt
pmn
lower
lymphocyt
wors
outcom
uncertain
sar
patient
lower
lymphocyt
platelet
normal
higher
pmn
recent
shown
sar
patient
appear
alter
mitogenactiv
protein
kinas
activ
pattern
differ
leukocyt
associ
increment
immunosuppress
mediat
howev
answer
lymphopenia
occur
sar
patient
odonnel
et
al
propos
apoptosi
may
explain
lymphopenia
sar
leukocyt
apoptosi
play
critic
role
variou
immun
reaction
infecti
diseas
one
major
apoptot
pathway
fa
ligand
fasl
fa
pathway
key
molecul
execut
fasmedi
apoptosi
solubl
vascular
cell
adhes
implic
mani
vascul
disord
leukocyt
adhes
migrat
patient
sar
lymphopenia
extens
lung
tissu
damag
thu
propos
plasma
level
might
correl
vascular
sequestr
result
lymphopenia
tissu
damag
sar
infect
altern
hypothesi
lymphopenia
could
relat
increas
plasma
fasl
intracellular
cascad
agematch
casecontrol
design
measur
plasma
sfasl
intracellular
cleav
express
differ
leukocyt
sar
patient
sought
explor
relationship
lymphopenia
thrombocytopenia
clinic
manifest
plasma
sfasl
level
well
intracellular
cleav
level
sar
patient
april
index
case
sar
patient
taipei
initi
present
flank
pain
fever
admit
hospit
kaohsiung
southern
taiwan
patient
suspect
sar
april
may
cluster
sar
patient
includ
patient
famili
caregiv
health
care
worker
develop
probabl
sar
recruit
previous
healthi
studi
casecontrol
design
recruit
one
three
sar
patient
immun
studi
simultan
includ
one
three
agematch
healthi
adult
expos
sar
patient
control
confirm
sar
infect
determin
definit
exposur
histori
posit
rtpcr
detect
coronaviru
acut
stage
detect
coronaviru
specif
antibodi
convalesc
stage
studi
proceed
safeti
protocol
blood
collect
safeti
procedur
studi
approv
institut
review
board
hospit
progress
sar
summar
three
stage
incub
period
ii
febril
pneumon
stage
iii
recov
stage
fulmin
hypoxemia
associ
adult
respiratori
distress
syndrom
ard
therefor
collect
whole
blood
ml
ethylenedinitrilotetraacet
acid
edta
contain
blood
collect
tube
first
week
admiss
acut
phase
well
third
week
admiss
convalesc
phase
blood
sampl
separ
plasma
blood
cell
centrifug
g
min
upper
plasma
layer
harvest
cytokin
determin
heat
inactiv
min
potenti
virus
bottom
blood
cell
separ
red
blood
cell
white
blood
cell
wbc
dextran
sediment
wbc
drawn
formaldehydecontain
eppendorf
tube
vv
inactiv
possibl
viabl
organ
fixat
leukocyt
whole
procedur
open
origin
blood
collect
tube
oper
procedur
laboratori
blood
collect
tube
autoclav
undertak
standard
biohazard
wast
manag
level
measur
enzymelink
immunosorb
assay
elisa
kit
r
system
inc
minneapoli
mn
solubl
fasl
level
also
measur
elisa
kit
bender
medsystem
vienna
austria
plasma
plasma
aliquot
ml
use
individu
elisa
assay
previous
describ
flow
cytometr
detect
intracellular
cleav
level
perform
previous
describ
experi
formaldehydefix
leukocyt
subject
cell
permeabil
methanol
vv
min
wash
twice
pb
method
shown
rapid
sensit
classic
method
human
cell
formaldehydefix
leukocyt
suspend
cell
per
ml
studi
permeabil
leukocyt
ml
aliquot
subject
dual
stain
cell
surfac
molecul
peconjug
mous
antihuman
antibodi
bd
pharmingen
inc
franklin
lake
ca
stain
intracellular
signal
molecul
rabbit
antihuman
cleav
antibodi
cell
signal
technolog
inc
beverli
min
follow
recognit
fitcconjug
goat
antirabbit
igg
antibodi
serotec
ltd
oxford
uk
anoth
stain
wash
twice
pb
reaction
suspend
ml
pb
flow
cytometr
analysi
differ
cleav
differ
leukocyt
popul
data
relat
quantiti
sfasl
present
mean
standard
error
p
valu
analyz
student
ttest
data
regard
geometr
mean
intens
percentag
posit
stain
cell
intracellular
cleav
level
patient
control
group
analyz
use
mannwhitney
utest
spearman
rho
correl
use
test
correl
lymphopenia
thrombocytopenia
sfasl
intracellular
cleav
level
fifteen
patient
age
normal
control
age
studi
sar
patient
previous
healthi
fever
differ
extent
pneumonia
chest
radiographi
shown
tabl
initi
present
profound
lymphopenia
rang
mean
per
l
p
thrombopenia
rang
mean
per
l
p
total
wbc
rang
mean
per
l
neutrophil
count
rang
mean
per
l
within
normal
limit
patient
p
prolong
activ
partial
thromboplastin
time
aptt
defin
clot
time
longer
normal
control
normal
pt
prothrombin
time
suggest
vascular
insult
hepat
insuffici
normal
elev
lactat
dehydrogenas
ldh
creatin
phosphokinas
cpk
also
note
patient
treat
protocol
initi
institut
ribavirin
mgm
per
day
first
day
load
dose
g
patient
receiv
steroid
methylprednisolon
mgkg
per
day
without
puls
therapi
mg
everi
h
day
progress
pneumon
ard
usual
occur
day
diseas
found
plasma
level
significantli
higher
sar
patient
normal
control
first
week
ill
vs
ngml
p
fig
elev
level
return
normal
third
week
fig
higher
level
significantli
correl
lower
total
leukocyt
platelet
p
respect
fig
c
lymphocyt
p
investig
role
apoptosi
lymphopenia
patient
sar
measur
plasma
sfasl
patient
sar
normal
control
plasma
sfasl
level
significantli
higher
sar
patient
normal
control
earli
stage
vs
ngml
p
fig
sfasl
level
remain
higher
third
week
p
fig
accord
spearman
rho
correl
analysi
sfasl
level
plasma
patient
sar
correl
level
p
fig
plasma
sfasl
level
howev
correl
total
wbc
p
thrombocytopenia
p
caspas
known
play
major
role
execut
apoptosi
mammalian
cell
use
formaldehyd
fix
peripher
blood
leukocyt
measur
intracellular
cleav
express
total
leukocyt
patient
sar
agematch
normal
control
shown
repres
experi
fig
found
sar
patient
increas
leukocyt
posit
intracellular
cleav
stain
summari
calcul
result
experi
leukocyt
posit
intracellular
cleav
stain
significantli
higher
sar
patient
control
fig
order
identifi
subtyp
leukocyt
higher
cleav
express
sar
patient
use
dual
stain
anticleav
antibodi
plu
antibodi
purpos
found
sar
patient
tend
higher
cleav
express
cell
healthi
control
fig
although
reach
signific
differ
cleav
express
cell
sar
patient
significantli
higher
acut
phase
convalesc
phase
fig
patient
sar
usual
rapid
progress
pneumon
even
develop
ard
pulmonari
fibrosi
second
third
week
diseas
histolog
examin
lung
necropsi
sar
patient
demonstr
infiltr
inflammatori
cell
associ
foami
macrophag
multinuclear
syncyti
cell
occa
sional
hemophagocyt
phagocyt
rais
possibl
immunopatholog
damag
lung
tissu
due
exagger
host
respons
uncontrol
viru
replic
lung
previous
report
apoptosi
lung
epitheli
cell
fa
ligat
may
involv
lung
injuri
fibrosi
find
plasma
sfasl
level
significantli
higher
sar
patient
whether
higher
plasma
sfasl
level
relat
apoptosi
circul
leukocyt
lung
tissu
damag
remain
determin
fact
sfasl
level
correl
level
total
leukocyt
platelet
count
suggest
elev
sfasl
plasma
may
relat
lymphopenia
tissu
damag
solubl
gener
site
vascular
insult
inflamm
elev
level
may
origin
shed
vascular
tissu
inflamm
perhap
act
competit
ligand
inhibit
leukocyt
adhes
inflam
vascular
endothelium
kitani
et
al
shown
inhibit
cell
prolifer
possibl
suppress
product
rose
et
al
show
could
activ
bind
cell
bind
disrupt
apoptosi
suggest
may
involv
adhes
chemotaxi
toward
endothelium
circul
lymphocyt
patient
sar
significantli
higher
level
first
week
ill
return
normal
level
third
week
elev
might
contribut
earli
vascular
insult
suppress
cell
function
assess
vascular
adhes
molecul
predict
sepsi
system
infect
recent
extens
review
result
show
level
correl
well
sever
inflamm
diseas
lack
specif
certain
infect
induc
endotheli
damag
remain
unclear
whether
vascular
insult
immunosuppress
associ
overwhelm
lung
infect
coinfect
caus
morbid
mortal
lymphopenia
found
mani
infect
includ
sar
patient
measl
tend
lymphopenia
due
inhibit
lymphocyt
prolifer
herp
vaccinia
infect
tend
inhibit
matur
lymphocyt
extens
leukocyt
apoptosi
implic
ebola
viru
infect
propos
lymphopenia
sar
patient
relat
cell
apoptosi
find
sar
patient
appear
higher
plasma
fasl
level
associ
higher
intracellular
cleav
posit
lymphocyt
acut
phase
sar
although
fasl
level
significantli
correl
lymphocyt
count
blood
may
cell
apoptosi
usual
requir
twostep
mechan
inhibit
cell
apoptosi
recent
shown
improv
surviv
septic
anim
taken
togeth
suggest
inhibit
lymphocyt
apoptosi
could
prevent
lymphopenia
sar
whether
correct
lymphopenia
would
improv
outcom
sar
may
never
known
